A Multifunctional Fe-Based Metal–Organic Framework With Ferroptosis for Synergistic Therapy

IF 3.7 2区化学 Q2 CHEMISTRY, APPLIED

Applied Organometallic Chemistry Pub Date : 2025-04-08 DOI:10.1002/aoc.70143

Lu Hong, Qiaoyu Chen, Lei Rao, Zhen Wang, Bing Wang, Qing He, Wenxin Lin

{"title":"A Multifunctional Fe-Based Metal–Organic Framework With Ferroptosis for Synergistic Therapy","authors":"Lu Hong, Qiaoyu Chen, Lei Rao, Zhen Wang, Bing Wang, Qing He, Wenxin Lin","doi":"10.1002/aoc.70143","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Generally, single cancer treatment is insufficient to achieve ideal therapeutic effect. Multimodal therapy has the potential to overcome efficacy challenges and reveals great promise in enhancing therapeutic effect. Herein, a combination treatment system (DOX@Fe-PBC) based on chemotherapy, chemodynamic therapy (CDT), and ferroptosis was constructed by loading anticancer drug doxorubicin hydrochloride (DOX) into Fe-based metal–organic framework (Fe-PBC). In simulated tumor microenvironment, the system released anticancer drug DOX to be a DNA intercalator and topoisomerase II inhibitor to realize chemotherapy (CT) and iron ions were delivered to induce Fenton reaction, which boost the generation of •OH, resulting in the enhancement of the effect of chemodynamic therapy (CDT). Meantime, the system could consume glutathione (GSH) to reduce the expression of glutathione peroxidase 4 (GPX4); then, lipid peroxides (LPO) were accumulated to realize ferroptosis. DOX@Fe-PBC provided an effective strategy of chemotherapy, CDT, and ferroptosis to realize ideal cancer treatment.</p>\n </div>","PeriodicalId":8344,"journal":{"name":"Applied Organometallic Chemistry","volume":"39 5","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Applied Organometallic Chemistry","FirstCategoryId":"92","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/aoc.70143","RegionNum":2,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, APPLIED","Score":null,"Total":0}

引用次数: 0

Abstract

Generally, single cancer treatment is insufficient to achieve ideal therapeutic effect. Multimodal therapy has the potential to overcome efficacy challenges and reveals great promise in enhancing therapeutic effect. Herein, a combination treatment system (DOX@Fe-PBC) based on chemotherapy, chemodynamic therapy (CDT), and ferroptosis was constructed by loading anticancer drug doxorubicin hydrochloride (DOX) into Fe-based metal–organic framework (Fe-PBC). In simulated tumor microenvironment, the system released anticancer drug DOX to be a DNA intercalator and topoisomerase II inhibitor to realize chemotherapy (CT) and iron ions were delivered to induce Fenton reaction, which boost the generation of •OH, resulting in the enhancement of the effect of chemodynamic therapy (CDT). Meantime, the system could consume glutathione (GSH) to reduce the expression of glutathione peroxidase 4 (GPX4); then, lipid peroxides (LPO) were accumulated to realize ferroptosis. DOX@Fe-PBC provided an effective strategy of chemotherapy, CDT, and ferroptosis to realize ideal cancer treatment.

查看原文本刊更多论文

一种多功能铁基金属-有机框架与铁下垂协同治疗

一般情况下，单一的癌症治疗不足以达到理想的治疗效果。多模式治疗具有克服疗效挑战的潜力，在提高治疗效果方面显示出巨大的希望。本研究通过将抗癌药物盐酸多柔比星（DOX）加载到铁基金属-有机框架（Fe-PBC）中，构建了基于化疗、化疗动力学治疗（CDT）和铁凋亡的联合治疗体系（DOX@Fe-PBC）。在模拟肿瘤微环境中，系统释放抗癌药物DOX作为DNA插入剂和拓扑异构酶II抑制剂实现化疗（CT），并递送铁离子诱导芬顿反应，促进•OH的生成，从而增强化疗（CDT）效果。同时，系统可消耗谷胱甘肽（GSH）降低谷胱甘肽过氧化物酶4 （GPX4）的表达；脂质过氧化物（LPO）积累，实现铁下垂。DOX@Fe-PBC提供了化疗、CDT和铁下垂的有效策略，以实现理想的癌症治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Applied Organometallic Chemistry 化学-无机化学与核化学

CiteScore

7.80

自引率

10.30%

发文量

408

审稿时长

2.2 months

期刊介绍： All new compounds should be satisfactorily identified and proof of their structure given according to generally accepted standards. Structural reports, such as papers exclusively dealing with synthesis and characterization, analytical techniques, or X-ray diffraction studies of metal-organic or organometallic compounds will not be considered. The editors reserve the right to refuse without peer review any manuscript that does not comply with the aims and scope of the journal. Applied Organometallic Chemistry publishes Full Papers, Reviews, Mini Reviews and Communications of scientific research in all areas of organometallic and metal-organic chemistry involving main group metals, transition metals, lanthanides and actinides. All contributions should contain an explicit application of novel compounds, for instance in materials science, nano science, catalysis, chemical vapour deposition, metal-mediated organic synthesis, polymers, bio-organometallics, metallo-therapy, metallo-diagnostics and medicine. Reviews of books covering aspects of the fields of focus are also published.